Maternal Obesity and Placental Dopamine Signaling Impact on Infant Neurodevelopment

35 mother-infant dyads from the OBESO cohort in Mexico City were studied to explore links between maternal obesity, placental dopamine, and infant neurodevelopment. Placental dopamine concentrations were quantified by ELISA, and expression of dopaminergic components like TH, COMT, VMAT2, DAT, and DRD2 was analyzed via Western blot. The study found reduced placental dopamine and altered expression of COMT, DAT, and VMAT2 associated with maternal obesity and altered infant Bayley-III scores.

Use Cases

• Correlating maternal pregestational BMI with placental dopamine concentrations based on ELISA measurements.
• Investigating the relationship between altered expression of dopaminergic components (COMT, DAT, VMAT2) and infant neurodevelopmental status based on Bayley-III scores.
• Exploring the impact of inadequate gestational weight gain on placental neuroendocrine pathways described in the results.

Strengths

• Includes data from 35 mother-infant dyads with detailed clinical and anthropometric variables.
• Quantifies placental dopamine via ELISA and analyzes expression of six key dopaminergic proteins (TH, COMT, VMAT2, OCT3, DAT, DRD2) via Western blot.
• Infant neurodevelopment was assessed using the standardized Bayley-III Scales at one month of age.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The sample size of 35 participants is relatively small, limiting generalizability as noted in the conclusions.

Provenance

Source

Nicole Soria-Reinoso via figshare.

Collection Method

Data collected from the OBESO cohort in Mexico City; placental dopamine quantified by ELISA, protein expression analyzed by Western blot.

Freshness

Last updated 2026-05-25 04:34:38; freshness should be verified.

Geography

Participants from Mexico City.